They therefore concluded that the maximum achievable BAT activation in these subjects far exceeded the effects of chenodeoxycholic acid, but that more potent bile acid BAT activators may have traction as anti‐obesity drugs. The gene discussed is BAAT; the disease is obesity due to melanocortin 4 receptor deficiency.